Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBIT Margin (2017 - 2025)

UroGen Pharma's EBIT Margin history spans 9 years, with the latest figure at 186.23% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 29882.0% year-over-year to 186.23%; the TTM value through Dec 2025 reached 32.14%, up 7492.0%, while the annual FY2025 figure was 32.14%, 7492.0% up from the prior year.
  • EBIT Margin reached 186.23% in Q4 2025 per URGN's latest filing, up from 99.65% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 187.44% in Q4 2022 to a low of 348.88% in Q1 2021.
  • Average EBIT Margin over 5 years is 104.27%, with a median of 115.49% recorded in 2024.
  • Peak YoY movement for EBIT Margin: soared 837326bps in 2021, then tumbled -24953bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 123.13% in 2021, then skyrocketed by 252bps to 187.44% in 2022, then crashed by -133bps to 62.09% in 2023, then crashed by -81bps to 112.59% in 2024, then soared by 265bps to 186.23% in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBIT Margin are 186.23% (Q4 2025), 99.65% (Q3 2025), and 171.17% (Q2 2025).